Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BBP 671

Next Previous
Search
Drug Profile

BBP 671

Alternative Names: BBP-671

Latest Information Update: 28 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer CoA Therapeutics
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Pantothenate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acidaemia; Pantothenate kinase-associated neurodegeneration
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acidaemia; Pantothenate kinase-associated neurodegeneration

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in Pantothenate Kinase Associated Neurodegeneration(In volunteers) in USA (PO)
  • 28 Aug 2023 No recent reports of development identified for preclinical development in Acidaemia in USA (PO)
  • 03 Nov 2022 BridgeBio Pharma plans a pivotal phase II/III trial for Pantothenate kinase-associated neurodegeneration in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top